{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:46:54Z","timestamp":1792277214397,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T00:00:00Z","timestamp":1463011200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Seattle Genetics, Inc."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.leukres.2016.02.010","type":"journal-article","created":{"date-parts":[[2016,2,28]],"date-time":"2016-02-28T19:20:00Z","timestamp":1456687200000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin"],"prefix":"10.1016","volume":"44","author":[{"given":"Uma","family":"Borate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Josephson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Schnadig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2016.02.010_bib0005","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2016.02.010_bib0010","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.hoc.2012.08.008","article-title":"New insights into the pathogenesis, diagnosis, and management of mastocytosis","volume":"26","author":"Fuller","year":"2012","journal-title":"Hematol. Oncol. Clin. N. Am."},{"issue":"7","key":"10.1016\/j.leukres.2016.02.010_bib0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/ajh.23459","article-title":"Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management","volume":"88","author":"Pardanani","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"23","key":"10.1016\/j.leukres.2016.02.010_bib0020","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.leukres.2016.02.010_bib0025","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.leukres.2016.02.010_bib0030","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2016.02.010_bib0035","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2016.02.010_bib0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.leukres.2016.02.010_bib0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.leukres.2004.05.003","article-title":"Successful treatment of systemic mastocytosis with high-dose interferon-alfa: long-term follow-up of a case","volume":"29","author":"Butterfield","year":"2005","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2016.02.010_bib0050","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-\u03b1: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2016.02.010_bib0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk. Res."},{"issue":"21","key":"10.1016\/j.leukres.2016.02.010_bib0060","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood.V116.21.1982.1982","article-title":"Long term efficacy and safety of cladribine in adult systemic mastocytosis: a French multicenter study of 44 patients. [ASH Annual Meeting Abstracts, Abstract 1982]","volume":"116","author":"Hermine","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2016.02.010_bib0065","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"NEJM"},{"issue":"13","key":"10.1016\/j.leukres.2016.02.010_bib0070","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2016.02.010_bib0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2016.02.010_bib0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJM200101253440415","article-title":"Treatment of systemic mast-cell disease with cladribine","volume":"344","author":"Tefferi","year":"2001","journal-title":"NEJM"},{"issue":"1\u20132","key":"10.1016\/j.leukres.2016.02.010_bib0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10428199909145712","article-title":"Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas","volume":"35","author":"Rummel","year":"1999","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.leukres.2016.02.010_bib0090","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2016.02.010_bib0095","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/his.12221","article-title":"CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis","volume":"63","author":"Morgado","year":"2013","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.leukres.2016.02.010_bib0100","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/modpathol.2010.224","article-title":"Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis","volume":"24","author":"Sotlar","year":"2011","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.leukres.2016.02.010_bib0105","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3109\/10428194.2010.550072","article-title":"Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms","volume":"52","author":"Valent","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.leukres.2016.02.010_bib0110","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2014monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2016.02.010_bib0115","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.leukres.2016.02.010_bib0120","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2016.02.010_bib0125","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.leukres.2016.02.010_bib0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0145-2126(02)00168-6","article-title":"Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria","volume":"27","author":"Valent","year":"2003","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2016.02.010_bib0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2010.01407.x","article-title":"A critical reappraisal of treatment response criteria in systemic mastocytosis and a proposal for revisions","volume":"84","author":"Pardanani","year":"2010","journal-title":"Eur. J. Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2016.02.010_bib0140","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2016.02.010_bib0145","doi-asserted-by":"crossref","first-page":"e45244","DOI":"10.1371\/journal.pone.0045244","article-title":"Distinct motifs in the intracellular domain of human CD30 differentially activate canonical and alternative transcription factor NF-\u03baB signaling","volume":"7","author":"Buchan","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.leukres.2016.02.010_bib0150","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood.V83.8.2045.2045","article-title":"Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines","volume":"83","author":"Gruss","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2016.02.010_bib0155","first-page":"1123","article-title":"Classical Hodgkin\u2019s disease: clinial impact of the immunophenotype","volume":"151","author":"von Wasielewski","year":"1997","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.leukres.2016.02.010_bib0160","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5","article-title":"Expression of Ki-1 anitgen (CD30) in mesenchymal tumors","volume":"66","author":"Mechtersheimer","year":"1990","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2016.02.010_bib0165","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1182\/blood.V89.6.2048","article-title":"CD30 ligand is frequently expressed in human hematopoietic malignancies of myeloid and lymphoid origin","volume":"89","author":"Gattei","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2016.02.010_bib0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.iac.2014.01.006","article-title":"CD30 in systemic mastocytosis","volume":"34","author":"van Anrooij","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"issue":"1","key":"10.1016\/j.leukres.2016.02.010_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10072","article-title":"Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it: proposals of the Spanish Network on Mastocytosis (REMA)","volume":"58","author":"Escribano","year":"2004","journal-title":"Cytometry B Clin. Cytom."},{"issue":"3","key":"10.1016\/j.leukres.2016.02.010_bib0180","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"issue":"26","key":"10.1016\/j.leukres.2016.02.010_bib0185","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Indentification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2016.02.010_bib0190","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"10","key":"10.1016\/j.leukres.2016.02.010_bib0195","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3109\/10428194.2012.666543","article-title":"Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure","volume":"53","author":"Nathwani","year":"2012","journal-title":"Leuk. Lymphoma"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261630025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261630025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T12:08:05Z","timestamp":1620994085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261630025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":39,"alternative-id":["S014521261630025X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.010","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2016.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}